The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Dual-SERS biosensor for one-step detection of microRNAs in exosome and residual plasma of blood samples for diagnosing pancreatic cancer
Abstract
MicroRNAs have been proved to be the biomarker for early detection of pancreatic cancer and the precisely quantitation of the MicroRNA-10b in the blood samples even can distinguish pancreatic cancer from chronic pancreatitis (CP) and normal controls (NC). In this study, we developed a DSN-assisted dual-SERS biosensor for microRNA-10b in exosome and residual plasma of blood samples detection based on the Fe3O4 @Ag-DNA-Au@Ag@DTNB (SERS tag) conjugates. In presence of target microRNA, it can hybridized with the complementary DNA probes. DSN enzyme was then added to selectively cleaves the DNA probe of the DNA/microRNA duplex, SERS tags can be released from the Fe3O4@Ag and SERS intensity quenching can be triggered, the released microRNA can enter the cycle to decluster other DNA and SERS tags. Due to the dual-SERS enhancement of the Fe3O4@Ag-SERS tag conjugates and the recycling signal amplification, a detection limit of 1 aM with single-base recognition can be performed by one step. The target microRNA in plasma-derived exosome and residual supernatant plasma of blood samples from pancreatic ductal adenocarcinoma (PDAC), chronic pancreatitis (CP) and normal controls (NC) were directly quantified and significant SERS signal distinction can be found among them. The precise quantitation, one-step and one-pot operation can ensure this assay a promising future for point-of-care cancer diagnosis technology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06174 · Cited by 2,605 · cited 1×
“5d, we found that the SERS intensity of the PANC-01 and MCF-7 samples were much lower than that of HPDE6-C7 and MCF10A respectively, which proves the high levels of microRNA-10b in the cancer cell lines and can be used as cancer biomarkers (Ma et al., 2007; Sempere et al., 2010).”
BackgroundHidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570 · cited 1×
“Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy characterized by an abundant stroma, marked resistance to chemotherapy and radiotherapy, and advanced stage at clinical presentation precluding resection in 80% of patients (Ellis et al., 2009; Hidalgo, 2010).”
BackgroundDetection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers
Kim, J., Bamlet, W. R., Oberg, A. L., Chaffee, K. G., Donahue, G., Cao, X.-J., Chari, S., Garcia, B. A., Petersen, G. M., & Zaret, K. S. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5583 · Cited by 269
Ellis, J., Lin, J., Walsh, A., Lo, C., Shepherd, F. A., Moore, M., Li, M., Gagliese, L., Zimmermann, C., & Rodin, G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4864 · Cited by 128
Cited by
Exosomes as a new frontier of cancer liquid biopsy
Yu, D., Li, Y., Wang, M., Gu, J., Xu, W., Cai, H., Fang, X., & Zhang, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01509-9 · Cited by 855
Biosensor nanoengineering: Design, operation, and implementation for biomolecular analysis
Purohit, B., Vernekar, P. R., Shetti, N. P., & Chandra, P. (2020) · Sensors International · doi:10.1016/j.sintl.2020.100040 · Cited by 421
Analysis of extracellular vesicles as emerging theranostic nanoplatforms
Xing, Y., Cheng, Z., Wang, R., Lv, C., James, T. D., & Yu, F. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213506 · Cited by 67
Metadata
- Authors
- Pang, Y., Wang, C., Lu, L., Wang, C., Sun, Z., & Xiao, R.
- Venue
- Biosensors and Bioelectronics
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 130
- Pages
- 204-213
- ISSN
- 0956-5663 (ISSN-L)
- OpenAlex
- W2913606481
- Cited by
- 251
- References
- 5
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.